Literature DB >> 25134852

Improvements in lung function and height among cohorts of 6-year-olds with cystic fibrosis from 1994 to 2012.

Donald R VanDevanter1, David J Pasta2, Michael W Konstan3.   

Abstract

OBJECTIVE: To characterize spirometry and height changes in cohorts of 6-year-old children with cystic fibrosis (CF). STUDY
DESIGN: Global Lung Initiative forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and FEV1/FVC, and the Centers for Disease Control and Prevention height-for-age (HFA) z-scores were generated for 6-year-old children from the Cystic Fibrosis Foundation Patient Registry each year between 1994 and 2012. Z-score mean differences were analyzed by the t test, and time trends of means were analyzed by least squares regression for all children and for subgroups of sex, F508del mutation genotype, Medicaid insurance, and prenatal/newborn screening identification. Z-score distributions were compared using the 2-sample Kolmogorov-Smirnov test.
RESULTS: A total of 11 670 children with CF were studied, of whom 50.5% were males, 50.2% had the F508del/F508del genotype, and 46.6% were insured by Medicaid. Mean HFA, FEV1, and FVC z-scores increased significantly over the period in the entire cohort and in all subgroups (P < .001), but FEV1/FVC z-scores were below normal and did not change significantly. In 2012, children identified by screening had significantly higher mean HFA (P = .002), FEV1 (P < .001), and FVC (P < .001) z-scores compared with children not screened, with 90% of FVC and 71.4% of FEV1z-scores greater than predicted by the normal distribution. FEV1/FVC z-scores were not different between the children who were and were not screened.
CONCLUSION: Consistent, significant increases in HFA, FEV1, and FVC occurred between 1994 and 2012, but FEV1/FVC, a measure of airway obstruction, did not change appreciably during this period. FVC and FEV1z-score distributions suggest that normative equation reference populations underpredict lung volumes of children with CF, but the reasons for this remain unclear.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25134852      PMCID: PMC4252623          DOI: 10.1016/j.jpeds.2014.06.061

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  20 in total

Review 1.  Cystic fibrosis.

Authors:  P B Davis; M Drumm; M W Konstan
Journal:  Am J Respir Crit Care Med       Date:  1996-11       Impact factor: 21.405

2.  Interpretative consequences of adopting the Global Lungs 2012 reference equations for spirometry for children and adolescents.

Authors:  Philip H Quanjer; Daniel J Weiner
Journal:  Pediatr Pulmonol       Date:  2013-09-20

3.  Progression of early structural lung disease in young children with cystic fibrosis assessed using CT.

Authors:  Lauren S Mott; Judy Park; Conor P Murray; Catherine L Gangell; Nicholas H de Klerk; Philip J Robinson; Colin F Robertson; Sarath C Ranganathan; Peter D Sly; Stephen M Stick
Journal:  Thorax       Date:  2011-12-26       Impact factor: 9.139

4.  Trends in the use of routine therapies in cystic fibrosis: 1995-2005.

Authors:  Michael W Konstan; Donald R VanDevanter; Lawrence Rasouliyan; David J Pasta; Ashley Yegin; Wayne J Morgan; Jeffrey S Wagener
Journal:  Pediatr Pulmonol       Date:  2010-08-17

Review 5.  The role of inflammation in the pathophysiology of CF lung disease.

Authors:  James F Chmiel; Melvin Berger; Michael W Konstan
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

Review 6.  Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs.

Authors:  Scott D Grosse; Coleen A Boyle; Jeffrey R Botkin; Anne Marie Comeau; Martin Kharrazi; Margaret Rosenfeld; Benjamin S Wilfond
Journal:  MMWR Recomm Rep       Date:  2004-10-15

7.  Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening.

Authors:  Peter D Sly; Siobhain Brennan; Catherine Gangell; Nicholas de Klerk; Conor Murray; Lauren Mott; Stephen M Stick; Philip J Robinson; Colin F Robertson; Sarath C Ranganathan
Journal:  Am J Respir Crit Care Med       Date:  2009-04-16       Impact factor: 21.405

8.  Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis.

Authors:  Drucy Borowitz; Karen A Robinson; Margaret Rosenfeld; Stephanie D Davis; Kathryn A Sabadosa; Stephanie L Spear; Suzanne H Michel; Richard B Parad; Terry B White; Philip M Farrell; Bruce C Marshall; Frank J Accurso
Journal:  J Pediatr       Date:  2009-12       Impact factor: 4.406

9.  Factors influencing outcomes in cystic fibrosis: a center-based analysis.

Authors:  Charles Johnson; Steven M Butler; Michael W Konstan; Wayne Morgan; Mary Ellen B Wohl
Journal:  Chest       Date:  2003-01       Impact factor: 9.410

10.  Air trapping on chest CT is associated with worse ventilation distribution in infants with cystic fibrosis diagnosed following newborn screening.

Authors:  Graham L Hall; Karla M Logie; Faith Parsons; Sven M Schulzke; Gary Nolan; Conor Murray; Sarath Ranganathan; Phil Robinson; Peter D Sly; Stephen M Stick; Luke Berry; Luke Garratt; John Massie; Lauren Mott; Srinivas Poreddy; Shannon Simpson
Journal:  PLoS One       Date:  2011-08-19       Impact factor: 3.240

View more
  9 in total

Review 1.  Use of FEV1 in cystic fibrosis epidemiologic studies and clinical trials: A statistical perspective for the clinical researcher.

Authors:  Rhonda Szczesniak; Sonya L Heltshe; Sanja Stanojevic; Nicole Mayer-Hamblett
Journal:  J Cyst Fibros       Date:  2017-01-20       Impact factor: 5.482

2.  Phenotypes of Rapid Cystic Fibrosis Lung Disease Progression during Adolescence and Young Adulthood.

Authors:  Rhonda D Szczesniak; Dan Li; Weiji Su; Cole Brokamp; John Pestian; Michael Seid; John P Clancy
Journal:  Am J Respir Crit Care Med       Date:  2017-08-15       Impact factor: 21.405

3.  Early Life Growth Trajectories in Cystic Fibrosis are Associated with Pulmonary Function at Age 6 Years.

Authors:  Don B Sanders; Aliza Fink; Nicole Mayer-Hamblett; Michael S Schechter; Gregory S Sawicki; Margaret Rosenfeld; Patrick A Flume; Wayne J Morgan
Journal:  J Pediatr       Date:  2015-09-02       Impact factor: 4.406

4.  Potential for Therapeutic Benefit among Cystic Fibrosis Populations Excluded from Clinical Trials or Labeling of Marketed Therapies.

Authors:  Donald R VanDevanter; Sonya L Heltshe; John J LiPuma
Journal:  Ann Am Thorac Soc       Date:  2016-11

Review 5.  Trends in Growth and Maturation in Children with Cystic Fibrosis Throughout Nine Decades.

Authors:  Kelly A Mason; Alan D Rogol
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-12       Impact factor: 6.055

6.  Screening for cystic fibrosis in New York State: considerations for algorithm improvements.

Authors:  Denise M Kay; Breanne Maloney; Rhonda Hamel; Melissa Pearce; Lenore DeMartino; Rebecca McMahon; Emily McGrath; Lea Krein; Beth Vogel; Carlos A Saavedra-Matiz; Michele Caggana; Norma P Tavakoli
Journal:  Eur J Pediatr       Date:  2015-08-21       Impact factor: 3.183

7.  Showing Value in Newborn Screening: Challenges in Quantifying the Effectiveness and Cost-Effectiveness of Early Detection of Phenylketonuria and Cystic Fibrosis.

Authors:  Scott D Grosse
Journal:  Healthcare (Basel)       Date:  2015-11-11

Review 8.  Association of growth and nutritional parameters with pulmonary function in cystic fibrosis: a literature review.

Authors:  Renan Marrichi Mauch; Arthur Henrique Pezzo Kmit; Fernando Augusto de Lima Marson; Carlos Emilio Levy; Antonio de Azevedo Barros-Filho; José Dirceu Ribeiro
Journal:  Rev Paul Pediatr       Date:  2016-04-16

9.  Flexible semiparametric joint modeling: an application to estimate individual lung function decline and risk of pulmonary exacerbations in cystic fibrosis.

Authors:  Dan Li; Ruth Keogh; John P Clancy; Rhonda D Szczesniak
Journal:  Emerg Themes Epidemiol       Date:  2017-11-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.